Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-20 03:05 | 2026-02-17 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | OPT+S | $29.02 | 8,500 | $246,655 | 387,075 |
| 2026-02-20 03:06 | 2026-02-18 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | Director, Officer | SELL | $29.35 | 10,916 | $320,373 | 20,729 |
| 2026-02-20 02:36 | 2026-02-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Officer | OPT+S | $26.17 | 45,000 | $1,177,862 | 25,000 |
| 2026-02-20 02:38 | 2026-02-17 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Director | SELL | $26.18 | 1,230 | $32,196 | 22,647 |
| 2026-02-20 02:10 | 2026-02-18 | GERN | GERON CORP | ROBERTSON MICHELLE | Officer | OPT+S | $1.94 | 9,855 | $19,119 | 17,645 |
| 2026-02-20 01:42 | 2026-02-17 | IRON | Disc Medicine, Inc. | Franchi Jean M. | Officer | SELL | $64.51 | 11,156 | $719,727 | 71,343 |
| 2026-02-20 01:25 | 2026-02-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $69.33 | 5,894 | $408,613 | 108,231 |
| 2026-02-20 00:28 | 2026-02-17 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania | Officer | SELL | $483.52 | 977 | $472,395 | 48,650 |
| 2026-02-20 00:31 | 2026-02-19 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $476.34 | 8,300 | $3,953,588 | 36,781 |
| 2026-02-20 00:02 | 2026-02-17 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | Officer | SELL | $8.63 | 378 | $3,262 | 99,429 |
| 2026-02-19 01:18 | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Merendino Lauren | Officer | OPT+S | $11.60 | 5,814 | $67,448 | 60,157 |
| 2026-02-19 00:26 | 2026-02-13 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Biller Jonathan | Officer | SELL | $499.00 | 988 | $493,012 | 16,838 |
| 2026-02-19 00:23 | 2026-02-13 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bhatia Sangeeta N. | Director | SELL | $500.00 | 266 | $133,000 | 4,299 |
| 2026-02-19 00:30 | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | Officer | OPT+S | $8.47 | 75 | $635 | 8,557 |
| 2026-02-19 00:30 | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | Officer | OPT+S | $8.47 | 89 | $754 | 7,677 |
| 2026-02-19 00:05 | 2026-02-13 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $63.00 | 291 | $18,333 | 450,335 |
| 2026-02-19 00:30 | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | DesRosier Thomas | Officer | OPT+S | $8.47 | 78 | $661 | 7,789 |
| 2026-02-19 01:38 | 2026-02-13 | RCKT | ROCKET PHARMACEUTICALS, INC. | Militello John | Officer | SELL | $3.31 | 3,726 | $12,341 | 92,176 |
| 2026-02-19 01:33 | 2026-02-13 | RCKT | ROCKET PHARMACEUTICALS, INC. | Shah Gaurav | Officer | SELL | $3.31 | 12,279 | $40,668 | 1,052,045 |
| 2026-02-19 01:18 | 2026-02-13 | AVDL | AVADEL PHARMACEUTICALS PLC | Weiss Asset Management LP | SELL | $21.00 | 11,112,052 | $233,353,092 | 0 | |
| 2026-02-19 05:11 | 2026-02-17 | JNJ | JOHNSON & JOHNSON | Broadhurst Vanessa | Officer | OPT+S | $243.39 | 6,197 | $1,508,288 | 23,003 |
| 2026-02-19 05:11 | 2026-02-18 | JNJ | JOHNSON & JOHNSON | Schmid Timothy | Officer | OPT+S | $244.33 | 22,623 | $5,527,507 | 26,769 |
| 2026-02-19 05:12 | 2026-02-17 | JNJ | JOHNSON & JOHNSON | REED JOHN C | Officer | OPT+S | $243.00 | 53,931 | $13,105,233 | 10,658 |
| 2026-02-19 05:12 | 2026-02-17 | JNJ | JOHNSON & JOHNSON | Wolk Joseph J | Officer | OPT+S | $242.80 | 89,654 | $21,767,830 | 14,000 |
| 2026-02-19 05:12 | 2026-02-13 | JNJ | JOHNSON & JOHNSON | Swanson James D. | Officer | OPT+S | $243.39 | 62,080 | $15,109,757 | 25,698 |
| 2026-02-19 03:33 | 2026-02-13 | MPLT | MapLight Therapeutics, Inc. | Malenka Robert C. | Director | SELL | $18.21 | 12,116 | $220,632 | 339,254 |
| 2026-02-19 03:40 | 2026-02-13 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $51.68 | 14,080 | $727,646 | 36,680 |
| 2026-02-19 03:01 | 2026-02-17 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | Director, Officer | OPT+S | $39.19 | 14,583 | $571,579 | 288,976 |
| 2026-02-19 02:34 | 2026-02-17 | BBIO | BridgeBio Pharma, Inc. | Scott Randal W. | Director | OPT+S | $75.46 | 10,000 | $754,557 | 11,589 |
| 2026-02-19 02:36 | 2026-02-17 | BBIO | BridgeBio Pharma, Inc. | Trimarchi Thomas | Officer | SELL | $74.72 | 13,600 | $1,016,147 | 336,585 |
| 2026-02-19 02:39 | 2026-02-17 | BBIO | BridgeBio Pharma, Inc. | Apuli Maricel | Officer | SELL | $74.31 | 510 | $37,898 | 123,945 |
| 2026-02-19 02:11 | 2026-02-13 | ARVN | Arvinas Inc. | Loomis David K | Officer | SELL | $11.89 | 1,016 | $12,080 | 30,800 |
| 2026-02-19 02:12 | 2026-02-13 | ARVN | Arvinas Inc. | Berkowitz Noah | Officer | SELL | $11.89 | 5,685 | $67,595 | 163,938 |
| 2026-02-19 02:12 | 2026-02-17 | PTGX | Protagonist Therapeutics, Inc | Williams Lewis T | Director | OPT+S | $82.42 | 18,000 | $1,483,560 | 7,825 |
| 2026-02-19 02:13 | 2026-02-13 | ARVN | Arvinas Inc. | Cacace Angela M | Officer | SELL | $11.89 | 4,592 | $54,599 | 151,232 |
| 2026-02-19 02:14 | 2026-02-13 | ARVN | Arvinas Inc. | Saik Andrew | Officer | SELL | $11.89 | 5,134 | $61,043 | 159,267 |
| 2026-02-19 02:16 | 2026-02-13 | ARVN | Arvinas Inc. | Teel Randy | Director, Officer | SELL | $11.89 | 4,403 | $52,352 | 154,482 |
| 2026-02-19 01:57 | 2026-02-13 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $26.49 | 200,000 | $5,298,000 | 1,654,597 |
| 2026-02-19 01:42 | 2026-02-13 | RCKT | ROCKET PHARMACEUTICALS, INC. | Wilson Martin | Officer | SELL | $3.31 | 12,253 | $40,582 | 683,376 |
| 2026-02-19 01:13 | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | VASCONCELLES MICHAEL | Officer | OPT+S | $11.60 | 2,728 | $31,647 | 4,397 |
| 2026-02-19 01:14 | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | Director, Officer | OPT+S | $11.60 | 15,459 | $179,338 | 204,603 |
| 2026-02-19 01:16 | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | Officer | OPT+S | $11.60 | 6,065 | $70,359 | 312,025 |
| 2026-02-19 01:17 | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | Officer | OPT+S | $11.60 | 6,395 | $74,188 | 72,694 |
| 2026-02-19 00:43 | 2026-02-13 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania | Officer | SELL | $499.99 | 1,500 | $749,985 | 46,132 |
| 2026-02-19 00:30 | 2026-02-13 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | Director, Officer | SELL | $7.78 | 13,871 | $107,952 | 174,316 |
| 2026-02-19 00:30 | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Director | OPT+S | $8.47 | 259 | $2,194 | 11,577 |
| 2026-02-19 00:30 | 2026-02-13 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Director | BUY | $1.31 | 268,497 | $352,886 | 1,654,186 |
| 2026-02-19 00:31 | 2026-02-17 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $480.75 | 22,500 | $10,816,956 | 0 |
| 2026-02-19 00:31 | 2026-02-13 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Moran Sean F. | Officer | SELL | $7.78 | 4,701 | $36,588 | 96,694 |
| 2026-02-19 00:32 | 2026-02-17 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Hodgson Ian | Officer | SELL | $7.38 | 847 | $6,253 | 51,080 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.